A novel canine favored CpG oligodeoxynucleotide capable of enhancing the efficacy of an inactivated aluminum-adjuvanted rabies vaccine of dog use

被引:11
作者
Ren, Jiling [1 ]
Sun, Luguo [2 ]
Yang, Liang [2 ]
Wang, Hua [2 ]
Wan, Min [2 ]
Zhang, Peiyin [2 ]
Yu, Hongtao [3 ]
Guo, Yan [3 ]
Yu, Yongli [1 ]
Wang, Liying [2 ]
机构
[1] Jilin Univ, Dept Immunol, Norman Bethune Coll Med, Changchun 130021, Peoples R China
[2] Jilin Univ, Dept Mol Biol, Norman Bethune Coll Med, Changchun 130021, Peoples R China
[3] Changchun Inst Biol Prod, Changchun 130021, Peoples R China
关键词
CpG ODN; Rabies vaccine; Dog; HERPESVIRUS-1; GLYCOPROTEIN-D; BLOOD MONONUCLEAR-CELLS; IMMUNE-RESPONSES; ANTIBODY-RESPONSE; HEPATITIS-B; T-CELLS; DNA; ACTIVATION; MECHANISM; MOTIFS;
D O I
10.1016/j.vaccine.2009.12.077
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
071005 [微生物学]; 100108 [医学免疫学];
摘要
In order to develop novel canine CpG ODNs as adjuvant for rabies vaccine of dog use, a panel of CpG ODNs containing different CpG motifs was designed and screened for their ability to induce the proliferation of canine splenocytes. Three AACGTT motif-containing CpG ODNs, designated as YW07, YW08 and YW09, respectively, were outshined with stronger ability to activate canine immune cells. The CpG ODNs were tested for their adjuvant activity for rabies vaccine in mice and dogs. It was found that YW07 could facilitate the rabies vaccine to induce more vigorous and long-lasting specific antibody response in mice and dogs, respectively. These findings suggest that YW07, a canine favored CpG ODN, could be used as a novel adjuvant for developing more efficient rabies vaccine of dog use. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2458 / 2464
页数:7
相关论文
共 30 条
[1]
BELOTTO AJ, 1988, REV INFECT DIS, V10, pS693
[2]
Cytotoxic T cells and viral hepatitis [J].
Chisari, FV .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (07) :1472-1477
[3]
CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity [J].
Chu, RS ;
Targoni, OS ;
Krieg, AM ;
Lehmann, PV ;
Harding, CV .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (10) :1623-1631
[4]
CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B® HBV vaccine in healthy adults:: A double-blind phase I/II study [J].
Cooper, CL ;
Davis, HL ;
Morris, ML ;
Efler, SM ;
Al Adhami, M ;
Krieg, AM ;
Cameron, DW ;
Heathcote, J .
JOURNAL OF CLINICAL IMMUNOLOGY, 2004, 24 (06) :693-701
[5]
CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans [J].
Davis, HL ;
Suparto, I ;
Weeratna, R ;
Jumintarto ;
Iskandriati, D ;
Chamzah, S ;
Ma'ruf, A ;
Nente, C ;
Pawitri, D ;
Krieg, AM ;
Heriyanto ;
Smits, W ;
Sajuthi, D .
VACCINE, 2000, 18 (18) :1920-1924
[6]
CpG DNA: A potent signal for growth, activation, and maturation of human dendritic cells [J].
Hartmann, G ;
Weiner, GJ ;
Krieg, AM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (16) :9305-9310
[7]
Mechanism and function of a newly identified CpG DNA moth in human primary B cells [J].
Hartmann, G ;
Krieg, AM .
JOURNAL OF IMMUNOLOGY, 2000, 164 (02) :944-952
[8]
Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo [J].
Hartmann, G ;
Weeratna, RD ;
Ballas, ZK ;
Payette, P ;
Blackwell, S ;
Suparto, I ;
Rasmussen, WL ;
Waldschmidt, M ;
Sajuthi, D ;
Purcell, RH ;
Davis, HL ;
Krieg, AM .
JOURNAL OF IMMUNOLOGY, 2000, 164 (03) :1617-1624
[9]
Rabies in China: An Update [J].
Hu, Ronglinag ;
Tang, Qing ;
Tang, Jianrong ;
Fooks, Anthony R. .
VECTOR-BORNE AND ZOONOTIC DISEASES, 2009, 9 (01) :1-11
[10]
CpG-containing oligodeoxynucleotides, in combination with conventional adjuvants, enhance the magnitude and change the bias of the immune responses to a herpesvirus glycoprotein [J].
Ioannou, XP ;
Gomis, SM ;
Karvonen, B ;
Hecker, R ;
Babiuk, LA ;
Littel-van den Hurk, SV .
VACCINE, 2002, 21 (1-2) :127-137